Background: The evidence base for the diagnosis and management of amyotrophic lateral
sclerosis (ALS) is weak. Objectives: To provide evidence‐based or expert recommendations …

Amyotrophic lateral sclerosis (ALS) is characterised by the progressive degeneration of
upper and lower motor neurons. Besides motor neuron degeneration, ALS is associated …

Most health-care professionals are trained to promote and maintain life and often have
difficulty when faced with the often rapid decline and death of people with terminal illnesses …

Advances in stem cell biology have generated intense interest in the prospect of
transplanting stem cells into the nervous system for the treatment of neurodegenerative …

Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease inevitably leading
to generalized muscle weakness and premature death. Sleep disturbances are extremely …

Background Non-invasive ventilation (NIV) and percutaneous gastrostomy (PEG) are
guideline-recommended interventions for symptom management in amyotrophic lateral …

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease primarily affecting the
upper and lower motor neurons. The lifetime risk of developing ALS is estimated at 1: 350 for …

Amyotrophic lateral sclerosis (ALS) is the most common adult onset motor neuron disease
with no effective disease modifying therapies at present. Spinal cord degeneration is a …

Amyotrophic lateral sclerosis (ALS) is a progressive, neurodegenerative, and inevitably fatal
disease. There is no cure for ALS and life expectancy is typically 2–5 years after symptom …

Background Amyotrophic lateral sclerosis (ALS) is a progressive and usually fatal
neurodegenerative disease. Survival from diagnosis varies considerably. Several prognostic …